Bleeding risk in hospitalized patients with COVID‐19 receiving intermediate‐or therapeutic doses of thromboprophylaxis
P Demelo‐Rodriguez, AI Farfán‐Sedano… - … of Thrombosis and …, 2021 - Wiley Online Library
Introduction Some local protocols suggest using intermediate or therapeutic doses of
anticoagulants for thromboprophylaxis in hospitalized patients with coronavirus disease …
anticoagulants for thromboprophylaxis in hospitalized patients with coronavirus disease …
[HTML][HTML] Bleeding risk in hospitalized patients with COVID‐19 receiving intermediate‐or therapeutic doses of thromboprophylaxis
P Demelo‐Rodriguez, AI Farfán‐Sedano… - Journal of Thrombosis …, 2021 - Elsevier
Introduction Some local protocols suggest using intermediate or therapeutic doses of
anticoagulants for thromboprophylaxis in hospitalized patients with coronavirus disease …
anticoagulants for thromboprophylaxis in hospitalized patients with coronavirus disease …
[HTML][HTML] Bleeding risk in hospitalized patients with COVID‐19 receiving intermediate‐or therapeutic doses of thromboprophylaxis
P Demelo‐Rodriguez, AI Farfán‐Sedano… - Journal of Thrombosis …, 2021 - jthjournal.org
Introduction Some local protocols suggest using intermediate or therapeutic doses of
anticoagulants for thromboprophylaxis in hospitalized patients with coronavirus disease …
anticoagulants for thromboprophylaxis in hospitalized patients with coronavirus disease …
Bleeding risk in hospitalized patients with COVID-19 receiving intermediate-or therapeutic doses of thromboprophylaxis
P Demelo-Rodriguez… - … of thrombosis and …, 2021 - pubmed.ncbi.nlm.nih.gov
Introduction Some local protocols suggest using intermediate or therapeutic doses of
anticoagulants for thromboprophylaxis in hospitalized patients with coronavirus disease …
anticoagulants for thromboprophylaxis in hospitalized patients with coronavirus disease …
[引用][C] Bleeding risk in hospitalized patients with COVID‐19 receiving intermediate‐or therapeutic doses of thromboprophylaxis
P Demelo‐Rodriguez, AI Farfán‐Sedano… - Journal of Thrombosis …, 2021 - cir.nii.ac.jp
Bleeding risk in hospitalized patients with COVID‐19 receiving intermediate‐ or therapeutic
doses of thromboprophylaxis | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
doses of thromboprophylaxis | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
[HTML][HTML] Bleeding risk in hospitalized patients with COVID‐19 receiving intermediate‐or therapeutic doses of thromboprophylaxis
P Demelo‐Rodriguez, AI Farfán‐Sedano… - … of Thrombosis and …, 2021 - ncbi.nlm.nih.gov
Methods We performed a cohort study of patients hospitalized for COVID‐19 that received
intermediate or therapeutic doses of anticoagulants from March 25 to July 22, 2020, to …
intermediate or therapeutic doses of anticoagulants from March 25 to July 22, 2020, to …
Bleeding risk in hospitalized patients with COVID-19 receiving intermediate-or therapeutic doses of thromboprophylaxis.
P Demelo-Rodriguez, AI Farfán-Sedano… - … of Thrombosis and …, 2021 - europepmc.org
Methods We performed a cohort study of patients hospitalized for COVID-19 that received
intermediate or therapeutic doses of anticoagulants from March 25 to July 22, 2020, to …
intermediate or therapeutic doses of anticoagulants from March 25 to July 22, 2020, to …
[引用][C] Bleeding risk in hospitalized patients with COVID-19 receiving intermediate-or therapeutic doses of thromboprophylaxis
P Demelo-Rodriguez… - Journal of …, 2021 - produccioncientifica.ucm.es